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History of tuberculosis is associated with lower
exhaled nitric oxide levels in HIV-infected children
Evgeniya Sovershaevaa, Katharina Kranzerb,c,d, Grace Mchughd,
Tsitsi Bandasond, Edith D. Majongab,d, Omar S. Usmanie,
Sarah Rowland-Jonesf, Tore Guttebergg, Trond Flægstadh,i,
Rashida A. Ferrandb,d and Jon Ø. Odlanda,j,k
Objective: HIV disrupts host defense mechanisms andmaintains chronic inflammation
in the lung. Nitric oxide is a marker of lung inflammation and can be measured in the
exhaled air. We investigated the relationship between exhaled nitric oxide (eNO), HIV
status and airway abnormalities in perinatally HIV-infected children aged 6–19 years.
Design: A cross-sectional study.
Methods: HIV-infected individuals on antiretroviral therapy and HIV-uninfected chil-
dren with no active tuberculosis (TB) or acute respiratory tract infection were recruited
from a public hospital in Harare, Zimbabwe. Clinical history was collected and
eNO testing and spirometry was performed. The association between eNO and
explanatory variables (HIV, FEV1 z-score, CD4þ cell count, viral load, history of
TB) was investigated using linear regression analysis adjusted for age, sex and time
of eNO testing.
Results: In total, 222 HIV-infected and 97 HIV-uninfected participants were included.
Among HIV-infected participants, 57 (25.7%) had a history of past TB; 56 (25.2%) had
airway obstruction, but no prior TB. HIV status was associated with lower eNO level
[mean ratio 0.79 (95% confidence interval, 95% CI 0.65–0.97), P¼0.03]. Within the
HIV-infected group, history of past TB was associated with lower eNO levels after
controlling for age, sex and time of eNO testing [0.79 (95% CI 0.67–0.94), P¼0.007].
Conclusion: HIV infection and history of TB were associated with lower eNO levels.
eNO levels may be a marker of HIV and TB-induced alteration in pulmonary physiol-
ogy; further studies focused on potential causes for lower eNO levels in HIV and TB are
warranted. Copyright  2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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Background
Access to antiretroviral therapy (ART) has substantially
increased survival of children with HIV, with increasing
numbers now reaching adolescence and adulthood.
However, it is becoming increasingly apparent that
HIV infection is associated with chronic comorbidities in
the ART era [1,2].
In recent years, several studies from sub-Saharan Africa
have shown that chronic respiratory symptoms and airway
obstruction are common among children taking ART [3–
6], with obliterative bronchiolitis and bronchiectasis being
common noncommunicable causes of chronic respiratory
symptoms [7–12]. Furthermore, ART is not fully
protective against tuberculosis (TB) and individuals with
HIV on ART have an estimated 10% four-year risk of
developing TB compared with a 10% lifetime risk in the
general population of South Africa [13,14]. Moreover,
children with HIVexperience more rapid TB progression,
poorer response to treatment and are at a higher risk of TB
recurrence [15,16]. The long-term consequences of TB
often persist despite successful treatment, adding to the
burden of chronic lung disease [17].
Even though the pathogenesis of chronic lung disease in
HIV-infected individuals is not completely understood,
chronic airway inflammation and oxidative stress are
thought to play a distinct role [12,18]. One of the markers
of airway inflammation is nitric oxide that is produced by
various cells in the body, including the respiratory tract.
Under normal physiological conditions, there is constant
production of NO in the lung that regulates broncho-
dilation, neurotransmission, mucous secretion and the
inflammatory response [19,20]. The presence of NO can
be easily measured in exhaled air using a noninvasive,
quantitative, standardized method [21]. Increased levels of
exhaled nitric oxide (eNO) are a well known marker of
eosinophilic airway inflammation in asthma, while
reduced eNO levels have been reported in patients with
active lung TB, cystic fibrosis and in smokers [22–24].
Increased eNO levels are explained by overexpression of
the inducible NO synthase (iNOS), which often
correlates with systemic and lung inflammation, while
decreased eNO levels may be due to lack of the substrate
(L-arginine); reduced activity of iNOS in the airways
(which may be directly inhibited as an immune evasion
mechanism by Mycobacterium tuberculosis) or thick mucus
that may inhibit the NO diffusion into exhaled air (e.g. in
cystic fibrosis) [25–27].
Current data suggest that eNO may be a useful tool to
guide asthma management in both children and adults
[28,29], though its clinical application for other lung
disorders is unclear. A recent study showed that increased
eNO levels may predict clinical response to inhaled
corticosteroids in adults with nonspecific respiratory
symptoms [30].
Data investigating the association between HIV infection
and eNO levels are scarce [31]. Although lower levels of
eNO were found in one study among 36 HIV-infected
patients [31] compared with HIV-uninfected healthcare
workers, no significant difference in eNO levels were
reported in patients with HIV-TB coinfection compared
with HIV-uninfected patients with TB [22,32]. No
studies so far have investigated the level of eNO in
children with HIV-associated chronic lung disease.
In this study, we aimed to compare the levels of eNO in
children with and without HIV and investigated the
association between eNO and history of TB and airway
obstruction in HIV-infected children on ART.
Materials and methods
Study population
This cross-sectional study was conducted between April
2017 and August 2018 as a substudy of a randomized
controlled clinical trial investigating the effect of
azithromycin in children with HIV-associated chronic
lung disease (BREATHE trial, clinicaltrials.gov identifier
NCT02426112). The detailed study protocol has been
published elsewhere [33]. Participants were eligible for
the trial if they were aged 6–19 years, had perinatally
acquired HIV and had been taking ART for at least 6
months, and had no evidence of active TB or acute
respiratory tract infection. The trial is being conducted in
Malawi and Zimbabwe, but the substudy was conducted
in Zimbabwe only at the Harare Central hospital
paediatric HIV clinic, the largest public sector HIV
clinic in Harare.
TB may cause lung tissue changes (bronchovascular
distortion, fibrotic lesions and cavitation) persisting
beyond the acute episode [17]; these morphological
changes may influence eNO levels. We expected to find a
high prevalence of past TB because of the high incidence
of TB in people living with HIV. Thus, we divided HIV-
infected participants into three groups on the basis of
clinical history and spirometry results: normal lung
function and no TB history; history of TB irrespective of
airway obstruction; and airway obstruction and no TB
history. Airway obstruction was defined as forced
expiratory volume in 1 s (FEV1) z-score less than -1.64
with no reversibility (<12% improvement in FEV1 after
salbutamol 200mg inhaled using a spacer).
In addition, a group of HIV-uninfected participants was
recruited from the same catchment area as the HIV-
infected group. HIV-uninfected children (were tested for
HIVat enrolment) aged 6–16 years with no prior history
of heart/lung diseases (including history of TB), no
reported chest pain after exercise, shortness of breath
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during exercise or chronic cough and normal lung
function were eligible for the study as a control group.
Ethical approval
The studywas approved by the London School ofHygiene
and Tropical Medicine Ethics Committee; the Harare
Central Hospital Ethics Committee; theMedicalResearch
Council of Zimbabwe; Regional Committee for Medical
and Health Research Ethics in Norway (2015/1650).
Written informed consent by guardian and assent by
participants aged less than 18 years were obtained. Those
aged 18 years and older gave independent consent.
Study procedures
A detailed questionnaire regarding demographic and
clinical history was administered to all participants.
Participants were explicitly asked about current and
previous respiratory symptoms (chronic cough, wheezing
and dyspnoea) in the past 3 months. Self-reported and/or
physician-diagnosed lung diseases and/or atopic disorders
including rhinitis and atopic dermatitis were recorded.
Participants were classified as having asthma based on
clinical history of diagnosed asthma or self-reported
symptoms of asthma (episodes of wheezing, nocturnal
tightness in the chest, attacks of shortness of breath
following strenuous activity, at rest or at night-time) or
treatment with asthma-specific medications (short-term/
long-term b2 agonists; inhaled corticosteroids; leukotri-
ene receptor antagonists; methylxanthines).
Measurement of exhaled nitric oxide
The level of eNO was measured by the electrochemical
analyser (NIOX VERO, Circassia, UK) according to
American Thoracic Society (ATS) guidelines [21] and
expressed in parts per billion (ppb). The calibration of the
machine and quality control were performed according to
the manufacturer’s instructions. The participants were
asked to sit and rest for a minimum of 5min before the
measurement. Repeated exhalations were performed in
order to obtain at least two measurements that agreed
within 10%. Measurements were taken with a minimum
of 30 s rest time in between. Up to six eNOmeasurement
attempts were made and the mean eNO value was
calculated from two eNO measurements with minimal
difference between them. All eNO measurements were
performed between 0800 and 1400 h and exact time of
the testing was recorded.
Spirometry
Spirometry was performed after eNO measurement using
EasyOne spirometer (ndd Medical Technologies Inc.,
Andover, Massachusetts, USA) according to the ATS
guidelines. FEV1 z-scoreswere calculated using prediction
equations from the Global Lung Function Initiative [34].
Laboratory tests
All participants provided blood samples for full blood
count, and for participants with HIV, also for HIV
viral load and CD4þ cell count testing. HIV viral load
was measured using the Gene Xpert assay, with a limit
of detection of 40 copies/ml (XpertTM HIV-1 Viral
Load; Cepheid, Sunnyvale, California, USA) and
CD4þ cell count was measured as a point of care test
using a PimaTM Analyser (Alere, Orlando, Florida,
USA). Anaemia was defined according to WHO
criteria (haemoglobin <11.5 g/dl for children 6–11.9
years; haemoglobin <12 g/dl for children 12–14.9 years;
haemoglobin <12 g/dl for girls aged 15 years; haemo-
globin <13 g/dl for boys aged 15 years) [35].
Data collection
Electronic record forms (for questionnaires) collected on
Google Nexus tablets (Google, Mountain View, Cali-
fornia, USA) with OpenDataKit software and paper
forms (for clinical tests) were used for data collection.
Data from paper forms were extracted using CARDIFF
TELEFORM character optical mark recognition soft-
ware (Version 10.9). Data were stored inMicrosoft Access
database (Microsoft, Redmond, Washington, USA).
Statistical analysis
All statistical analyses were performed using STATA
Version 14 (StataCorp LLC, College Station, Texas,
USA). Values for eNOwere presented as geometric mean
with 95% confidence interval. Weight-for age and
height-for-age z-scores were calculated using British
1990 Growth Reference Curves [36], with z-scores less
than -2 representing wasting and stunting, respectively.
Characteristics between study groups were compared
using Fisher’s exact test (for categorical parameters) and
Kruskal–Wallis or Wilcoxon rank sum test (for continu-
ous parameters). The values of eNO were not normally
distributed and therefore were log transformed to
approximate normality. The analyses were performed
with log-transformed eNO data and back transformed to
present geometric mean. The association between eNO
levels and a priori defined explanatory variables was
studied using linear regression analysis. Explanatory
variables included HIV status, age, sex, anthropometric
parameters, haemoglobin level, haematocrit, white blood
cell count, neutrophil count, eosinophil count, FEV1 z
score, atopic status, passive smoking, for all participants;
CD4þ cell count, viral load, history of TB and presence of
airway obstruction, for participants with HIV only. Age,
sex and exact time of eNO testing were adjusted for a
priori. Parameters were included into multivariable linear
regression model if they showed a significant effect on the
prediction of eNO level in age, sex and time of eNO
testing adjusted models at P value less than 0.05.
Adjustment for unbalanced parameters (for HIV-infected
group) was also performed. Variance inflation factor was
used to detect multicollinearity in the multivariable
models. Height was not included into multivariable
regression models due to high collinearity with age. The
linear association between eNO and continuous variables
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was estimated graphically. Residual analysis with residual
plots and normal probability plots of residuals confirmed
no violation of the linear regression assumptions.
Results
In total, 227 HIV-infected and 104 HIV-uninfected
children were enrolled. Five participants (n¼ 1 HIV-
infected, n¼ 4 HIV-uninfected) aged 6–7 years did not
understand the procedure and were excluded from the
study. Of the remaining participants, acceptable eNO
measurements were obtained from 225 HIV-infected and
98 HIV-uninfected children. A total of four participants
were excluded from the study for the following reasons:
abnormal spirometry (n¼ 1, HIV-uninfected) and miss-
ing spirometry data (n¼ 3, HIV-infected).
Baseline characteristics of study participants and their
distribution across the four groups are presented in Table
1. The median time on ART among HIV-infected
children was 6.6 years (IQR 4.0–8.4) and comparable
across the three different groups. HIV-infected children
overall were more likely to be wasted and stunted
compared with HIV-uninfected children (wasted: 41.9
vs. 3.1%, P< 0.001; stunted: 42.8 vs. 4.1%, P< 0.001).
Anaemia was more common in HIV-infected than HIV-
uninfected children (31.2 vs. 9.3%, P< 0.001). Exposure
to passive smoking was more common in HIV-infected
than HIV-uninfected participants.
Among HIV-infected participants, those with a history of
prior TB had significantly higher prevalence of wasting
than participants with no airway abnormalities (52.6 vs.
28.4%, P¼ 0.001, respectively). In addition, participants
with a history of prior TB received a protease inhibitor
based regimen more often than other two groups. The
prevalence of both stunting and wasting was higher in
participants with airway obstruction when compared
with those with no airway abnormalities (stunted: 58.9 vs.
33.0%, P< 0.001; wasted: 57.1 vs. 28.4%, P< 0.001).
HIV status was associated with lower eNO levels after
adjusting for age, sex and time of eNO testing [geometric
mean ratio 0.79 (95% CI 0.65–0.97), P¼ 0.03]. Among
HIV-infected participants, those with a history of TB had
significantly lower eNO levels than those without TB
whether they had airway obstruction [geometric mean
13.7 (95% CI 12.2–15.5) vs. 16.9 (95% CI 14.3–19.8),
P¼ 0.03] or had no airway abnormalities [geometric
mean 17.9 (95% CI 16.0–20.0), P¼ 0.003] (Fig. 1).
Linear regression analysis controlled for age, sex and time
of eNO testing confirmed the association between past
TB and lower eNO levels (Table 2).
The association between participant characteristics and
eNO levels in HIV-infected and HIV-uninfected
participants are presented in Tables 2 and 3, respectively.
The level of eNO increased with increasing age and
height in HIV-infected children. Higher haemoglobin
level and neutrophil count were associated with higher
eNO level in adjusted analysis. Female sex was associated
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Table 1. Characteristics of study participants.
HIV-infected
Variables
History of TB
(N¼57)
Airway obstruction,
but no history of TB
(N¼56)
No TB,
no obstruction
(N¼109)
HIV-uninfected
(N¼97)
Age (years), Median (IQR) 15 (12–18) 15 (13–18) 16 (12–18) 10 (7–12)
Female sex, N (%) 26 (45.6) 18 (32.1) 71 (65.1) 47 (48.4)
Wasting (weight for age z-score<2), N (%) 30 (52.6) 32 (57.1) 31 (28.4) 3 (3.1)
Stunted (height-for-age z-score<2), N (%) 26 (45.6) 33 (58.9) 36 (33.0) 4 (4.1)
Passive smoking, N (%) 21 (36.8) 15 (26.8) 25 (22.9) 3 (3.1)
Living in high-density area, N (%) 53 (94.6) 49 (96.1) 100 (93.5) 95 (97.9)
eNO level (ppb), geometric mean (95% CI) 13.7 (12.2–15.5) 16.9 (14.3–19.8) 17.9 (16.0–20.0) 16.5 (14.8–18.5)
FEV1 z-score, Median (IQR) 1.8 (2.3 to 1.3) 2.1 (2.7 to 1.9) 1.1 (1.3 to 0.4) 0.2 (0.6 to 0.3)
Presence of atopy (asthma, eczema,
allergic rhinitis), N (%)
12 (21.0) 12 (21.4) 13 (11.9) 10 (10.3)
Haemoglobin (g/dl), Median (IQR) 13 (11.9–13.7) 12.7 (11.6–13.6) 12.8 (11.7–14) 13.2 (12.4–13.9)
Haematocrit, %, Median (IQR) 36.7 (34.0–38.4) 35.2 (33.3–37.9) 36 (33.4–38.6) 36.3 (34.8–39)
White blood cell count (M109/l), Median (IQR) 4.3 (3.8–5.4) 4.6 (3.3–5.3) 4.2 (3.6–5) 5.3 (4.5–6.3)
Eosinophil count (M109/l), Median (IQR) 0.075 (0.04–0.12) 0.065 (0.02–0.13) 0.06 (0.03–0.16) 0.1 (0.06–0.2)
Neutrophil count (M109/l), Median (IQR) 1.7 (1.3–2.2) 1.7 (1.1–2.5) 1.8 (1.4–2.4) 2.2 (1.8–2.9)
Lymphocyte count (M109/l), Median (IQR) 2.0 (1.6–2.6) 2.1 (1.6–2.7) 2.0 (1.6–2.3) 2.3 (2.0–2.8)
Monocyte count (M109/l), Median (IQR) 0.39 (0.32–0.48) 0.39 (0.30–0.5) 0.35 (0.27–0.46) 0.47 (0.36–0.63)
Anaemia, N (%) 15 (26.8) 17 (32.7) 35 (32.7) 9 (9.3)
Viral load (log10 copies/ml), Median (IQR) 2.7 (1.6–4.0) 2.5 (1.6–3.7) 2.1 (1.6–3.4) –
CD4þ cell count (cells/ml), Median (IQR) 509 (339–702) 559 (326–728) 624 (355–779) –
Years on ART, Median (IQR) 6.8 (4.6–9.1) 5.9 (3.6–7.8) 6.5 (4.0–8.4) –
PI-based regimen, N (%) 25 (43.9) 12 (21.4) 12 (11.0) –
ART, antiretroviral therapy; IQR, interquartile range; eNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; PI, protease inhibitor.
with lower eNO level in adjusted analysis. Due to
imbalances in wasting, stunting and use of protease
inhibitor based regimen by HIV-infected groups, these
variables were adjusted for in multivariable analysis. On
multivariable linear regression, haemoglobin, neutrophil
count, history of TB and age remained significantly
associated with eNO levels in HIV-infected participants.
In HIV-uninfected individuals, anthropometric param-
eters (height and weight) were significantly positively
associated with eNO level in univariate analysis, though
the association became nonsignificant after accounting for
age, sex and time of eNO testing. Higher haemoglobin
level and haematocrit were associated with higher eNO
level, while wasting was associated with lower eNO level
in univariate and adjusted analysis. On multivariable
analysis, wasting, haemoglobin and age remained
significantly associated with eNO levels in HIV-
uninfected participants.
Discussion
Our study showed that children with HIV infection have
lower eNO levels than HIV-uninfected children. HIV-
infected childrenwith a prior historyof TBhad significantly
lower eNO levels than those without prior TB.
There are few data on the levels of eNO in HIV-infected
adults [31], and none among children. Two studies
reported lower eNO levels associated with HIV infection
among adults with [32] and without TB [31], mirroring
the results of our study. However, a study including 19
HIV-infected and 126 HIV-uninfected adults with TB
did not find any difference in eNO, but was likely
underpowered [22]. The observed low eNO levels in
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Fig. 1. Level of exhaled nitric oxide inHIV-infected andHIV-
uninfected participants. Horizontal lines indicate geometric
mean values.
Table 2. Analysis of factors associated with exhaled nitric oxide level in HIV-infected participants.
Unadjusted
analysis
Adjusted for age, sex and time
of eNO testing
Multivariable
model
Variables GMRa (95% CI) P GMRa (95% CI) P GMRa (95% CI) P
Age (years) 1.03 (1.00–1.05) 0.004 1.03 (1.01–1.05) 0.003 1.03 (1.01–1.05) 0.005
Female sex 0.89 (0.77–1.03) 0.13 0.85 (0.74–0.99) 0.04 0.86 (0.74–1.01) 0.07
Weight (kg) 1.01 (1.00–1.01) 0.002 1.01 (1.00–1.02) 0.16
Height (cm) 1.01 (1.00–1.02) <0.001 1.02 (1.01–1.03) <0.001
Weight-for-age z-score 1.01 (0.96–1–06) 0.72 1.00 (0.94–1.05) 0.94
Height-for-age z-score 1.06 (1.00–1.13) 0.07 1.05 (0.99–1.13) 0.12
Wasting (weight for age z-score<2) 0.97 (0.83–1.13) 0.68 0.99 (0.85–1.16) 0.95 1.01 (0.84–1.22) 0.89
Stunted (height-for-age z-score<2) 0.93 (0.80–1.08) 0.33 0.94 (0.81–1.09) 0.41 0.94 (0.80–1.12) 0.51
Passive smoking (ref. no) 1.19 (1.00–1.40) 0.04 1.17 (0.99–1.38) 0.06
History of tuberculosis 0.78 (0.67–0.90) 0.004 0.79 (0.67–0.94) 0.007 0.80 (0.68–0.95) 0.013
FEV1 z-score 1.01 (0.95–1.07) 0.73 0.98 (0.92–1.05) 0.59
FEV1 z-score<1.64 (airway obstruction) 0.92 (0.79–1.08) 0.33 0.92 (0.78–1.09) 0.33
Presence of atopy 0.94 (0.77–1.15) 0.54 0.94 (0.77–1.15) 0.55
Haemoglobin (g/dl2 ) 1.07 (1.03–1.12) 0.002 1.06 (1.01–1.11) 0.009 1.07 (1.02–1.12) 0.004
Haematocrit, % 1.02 (1.00–1.03) 0.023 1.01 (1.00–1.02) 0.12
White blood cell count (log transformed) 1.17 (0.92–1.49) 0.20 1.57 (0.90–2.71) 0.11
Eosinophil count (log transformed) 1.03 (0.97–1.10) 0.33 1.04 (0.97–1.11) 0.26
Neutrophil count (log transformed) 1.19 (1.05–1.35) 0.012 1.46 (1.07–1.99) 0.016 1.19 (1.05–1.36) 0.008
Lymphocyte count (log transformed) 0.91 (0.78–1.08) 0.28 0.96 (0.66–1.41) 0.84
Monocyte count (log transformed) 1.16 (0.96–1.40) 0.12 1.36 (0.89–2.08) 0.15
Anaemia (ref. no) 0.97 (0.82–1.14) 0.71 0.97 (0.83–1.15) 0.75
HIV viral load (log10 copies/ml) 1.00 (0.95–1.05) 0.95 0.99 (0.95–1.05) 0.86
CD4þ cell count (cells/ml) 1.00 (0.99–1.00) 0.07 1.00 (0.99–1.01) 0.34
Years on ART 0.99 (0.97–1.02) 0.70 0.98 (0.95–1.00) 0.13
PI-based regimen (NNRTI-based as ref.) 0.85 (0.71–1.02) 0.09 0.86 (0.72–1.03) 0.11 0.90 (0.75–1.08) 0.27
ART, antiretroviral therapy; CI, confidence interval; eNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; PI, protease inhibitor.
aGeometric mean ratio.
HIV-infected children may be explained by immunolog-
ical and pathophysiological mechanisms. Alveolar macro-
phages play a central role in the defense against bacterial
and mycobacterial infection; they may become infected
with HIVand constitute the primary reservoir of the virus
in the lung [37,38]. During HIV infection, alveolar
macrophage function is compromised [37], with evidence
of oxidative stress [39] and reduced ability to phagocytose
and kill bacteria [40,41]. HIV-associated chronic activa-
tion of inflammatory cells in the alveolar space may
further compromise the host response against infectious
stimuli [42,43]. Thus, low levels of eNO detected in
patients with HIV may reflect the inability of alveolar
macrophages to produce eNO as part of the lung innate
immune system. This may contribute to persistent lung
immune dysfunction.
eNO levels are known to increase with age. This needs to
be taken into consideration when interpreting eNO levels
measured in children. Values of eNO increase linearly
between 6 and 16 years in parallel with the somatic
growth [44]. The ATS guidelines recommend adjustment
for age when interpreting the eNO levels in children
younger than 12 years of age [45]. In addition, the
majority of published studies have reported an association
between height and eNO levels [46–49]. Total airway
mucosal surface area for NO diffusion increases with
increasing age and height, thus leading to higher eNO
levels [50]. In our study, both age and height were
significantly associated with eNO levels in HIV-infected
children. Given that HIV-infected children are generally
smaller than their HIV-uninfected peers, this might partly
explain the lower eNO levels among HIV-infected
children observed in our study.
An interesting finding of our study was that history of TB
in HIV-infected participants was associated with lower
eNO levels. No studies have investigated the level of
eNO in individuals with a history of TB, though a
number of studies were conducted in adult patients with
active lung TB [22,32,51]. At least two studies found that
eNO levels were lower in patients with newly diagnosed
untreated lung TB than healthy controls [22,32].
Moreover, one of these studies reported an association
between low eNO levels at the time of TB diagnosis and
severity of disease [22].
M. tuberculosis (Mtb)may persist in alveolar macrophages for
a prolonged period of time [52,53]. Nonreplicating
persistence of Mtb may maintain chronic airway inflam-
mation and may lead to lung fibrosis [17]. There is some
evidence from in-vitro studies that nitric oxide has a
protective role in the progression of lung fibrosis [54].
Thus, lower levels of eNO in patients treated for TB in our
study may reflect altered lung immune response mediating
the development of chronic lung complications.
No association was found between airway obstruction
measured as FEV1 z score less than -1.64 and eNO levels
in HIV-infected children. This is in line with several other
studies reporting no association between FEV1 and eNO
in adults with chronic obstructive lung disease [55,56],
implying that eNO has probably no pathophysiological
role in the obstruction, but rather a marker of the
underlying condition, as seen in eosinophilic inflamma-
tion in asthma patients [57].
In our study, we found significant positive associations
between several blood parameters and eNO levels. The
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Table 3. Analysis of factors associated with exhaled nitric oxide level in HIV-uninfected participants.
]Unadjusted
analysis
Adjusted for age, sex and time
of eNO testing
Multivariable
model
Variables GMRa (95% CI) P GMRa (95% CI) P GMRa (95% CI) P
Age 1.09 (1.05–1.13) <0.001 1.08 (1.05–1.12) <0.001 1.07 (1.03–1.11) 0.001
Female sex 1.25 (1.01–1.56) 0.04 1.14 (0.93–1.40) 0.21 1.14 (0.92–1.41) 0.22
Weight (kg) 1.02 (1.01–1.03) <0.001 1.01 (0.99–1.03) 0.42
Height (cm) 1.02 (1.00–1.02) <0.001 1.01 (0.99–1.03) 0.15
Weight-for-age z-score 1.00 (0.88–1.13) 0.99 1.00 (0.88–1.13) 0.99
Height-for-age z-score 1.04 (0.93–1.16) 0.50 1.04 (0.93–1.17) 0.50
Wasting (weight for age z-score<2) 0.45 (0.24–0.85) 0.014 0.45 (0.24–0.85) 0.015 0.52 (0.29–0.92) 0.03
Stunted (height-for-age z-score<2) 0.70 (0.40–1.22) 0.21 0.70 (0.40–1.23) 0.21
Passive smoking (ref. no) 1.52 (0.80–2.88) 0.20 1.12 (0.61–2.04) 0.71
FEV1 z-score 1.01 (0.87–1.18) 0.87 1.01 (0.86–1.18) 0.90
Presence of atopy 1.08 (0.75–1.56) 0.67 1.05 (0.75–1.47) 0.75
Haemoglobin (g/dl2) 1.13 (1.05–1.23) 0.003 1.09 (1.01–1.19) 0.031 1.09 (1.00–1.18) 0.04
Haematocrit, % 1.07 (1.04–1.11) <0.001 1.05 (1.01–1.08) 0.009
White blood cell count (log transformed) 0.89 (0.66–1.20) 0.45 0.94 (0.49–1.81) 0.86
Eosinophil count (log transformed) 1.03 (0.92–1.14) 0.62 1.05 (0.95–1.16) 0.32
Neutrophil count (log transformed) 0.97 (0.78–1.20) 0.76 1.06 (0.66–1.71) 0.79
Lymphocyte count (log transformed) 0.94 (0.64–1.37) 0.74 1.04 (0.45–2.40) 0.92
Monocyte count (log transformed) 0.81 (0.62–1.05) 0.12 0.78 (0.44–1.40) 0.41
Anaemia (ref. no) 1.13 (0.77–1.66) 0.52 1.13 (0.77–1.67) 0.53
CI, confidence interval; eNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s.
aGeometric mean ratio.
associations between haemoglobin level, haemotocrit and
eNO may reflect physiological processes at the level of
endothelium. Increased haematocrit results in increased
shear stress and production of NO. The positive
association between eNO and blood neutrophils
observed in HIV-infected participants may be explained
by the fact that neutrophils can produce nitric oxide in
response to foreign stimuli [58]. However, in cystic
fibrosis patients, an inverse correlation between blood
neutrophils and eNO levels was reported, which was
thought to be due to the ability of neutrophils to produce
superoxide that downregulates nitric oxide production
[24]. The observed associations emphasize the need to
interpret eNO results with caution. eNO levels are
influenced by a multitude of factors, including demo-
graphic, anthropometric and biological factors, thus
questioning the utility of eNO as a clinical tool in
conditions beyond asthma. Although noninvasive nature
and measurement simplicity make eNO testing an
attractive tool for resource-limited settings, it is too early
to forecast its applicability and clinical usefulness among
HIV-infected children with airway abnormalities in a
given setting.
The strengths of the study are its prospective design,
relatively large sample size, use of standardized protocol
for eNO testing and spirometry performed by well
trained nurses. Study limitations include self-report of TB
with no information regarding TB localization (pulmo-
nary or extrapulmonary), raising concerns of recall bias.
Among other determinants that may have an impact on
eNO levels and that were not assessed in the present study
are genetic factors (affecting the activity of nitric oxide
synthase), environmental factors (air pollution) and
socioeconomic factors.
In summary, our study shows that both HIV infection and
history of TB are associated with lower eNO levels, with
no association found between eNO and airway obstruc-
tion. The low eNO levels may be a marker of abnormal
pulmonary physiology due to perinatally acquired HIV
infection and post-TB lung changes. The role of nitric
oxide in the pathogenesis of HIV infection needs
further investigation.
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